The European Society for Medical Oncology (ESMO) Congress 2025 brought leading oncology experts together to share the latest advances shaping cancer care worldwide. Fast Five highlights key insights captured live from the Congress.
In this episode, Elizabeth Buchbinder, Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute, USA, discusses key developments across cutaneous and uveal melanoma, with a focus on updated ESMO guideline recommendations, emerging cellular therapies, and practice-changing clinical trial data.
- Key updates from the ESMO guidelines on cutaneous melanoma and implications for patient management
- Phase I results from the IMA203 trial of PRAME-directed T cell therapy in uveal melanoma
- How PRAME-targeted T cell therapy may change the uveal melanoma treatment landscape
- Emerging trends and novel therapies in melanoma to watch
The EMJ Oncology Journal is now published, featuring comprehensive coverage of ESMO 2025, including expert interviews, peer-reviewed articles, and a visual infographic, explore the latest insights now.
Disclosure: Elizabeth has received consulting fees from Immunocore, Merck, Zola, Obsidian, Anaveon, and Werewolf.
